Evidence for a rapid inhibitor to tissue plasminogen activator in plasma

Chmielewska, Joanna; Rånby, Mats; Wiman, Björn

doi:10.1016/0049-3848(83)90407-3

Cited by 491 publications

(182 citation statements)

References 8 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…The t-PA activity was expressed in IU/ml by reference to the World Health Organization First International Standard for t-PA coded 86/670 from the National Institute for Biological Standard and Control, Potters Bar, England. Plasma PAI-1 activity 35 was determined with a two-stage, indirect enzymatic assay based on the addition of excess t-PA (40 IU/ml) to the samples and measurement of the residual t-PA activity. One unit of PAI-1 activity was defined as the amount of PAI-1 that inhibits 1 IU of international t-PA standard.…”

Section: Methodsmentioning

confidence: 99%

Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus

et al. 2004

View full text Add to dashboard Cite

The aim of this double-blind, double-dummy, parallel group study was to compare the effects of delaprilmanidipine combination vs a irbesartan-hydrochlorothiazide combination on plasma tissue plasminogen activator (t-PA) and plasmogen activator inhibitor type I (PAI-l) activities in hypertensive patients with type II diabetes mellitus. After a 4-week run-in placebo period, 80 patients (37 male and 43 female), aged 41-65 years, were randomly allocated to an 8-week treatment with delapril 30 mg once daily or irbesartan 150 mg once daily. Thereafter, manidipine l0 mg once daily was added to delapril treatment and hydrochlorothiazide 12.5 mg to irbesartan treatment for a further 8 weeks. Blood pressure (BP), plasma t-PA and PAI-l activities were evaluated at the end of the run-in period, after 4-week monotherapy treatments, and at the end of the combination treatment periods. Both combination treatments, delapril-manidipine and irbesartan-hydrochlorothiazide, produced a greater reduction in systolic BP/diastolic BP (SBP/DBP) values (À27.6/21.8 mmHg and À26.4/20.2 mmHg, respectively) than the respective monotherapies (À15.2/ 11.7 mmHg with delapril and À16.3/11.3 mmHg with irbesartan). Delapril monotherapy significantly decreased plasma PAI-l activity (À10.4 IU/mI; Po0.05). The addition of manidipine produced a significant increase in t-PA activity ( þ 0.27 IU/mI); Po0.05). Irbesartan monotherapy did not significantly affect the fibrinolytic balance, whereas the addition of hydrochlorothiazide worsened it, producing a significant increase in PAI-l activity ( þ 9.5 IU/ml; Po0.05). In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it.

show abstract

Section: Methodsmentioning

confidence: 99%

Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus

et al. 2004

View full text Add to dashboard Cite

show abstract

“…It was evaluated in unstimulated plasma, by the method of Chmielewska et al [16], using a chromogenic substrate (CH3SO2-D-CHT-Gly-Arg-pNA.AcOH) and physiologic fibrin stimulation (Spectrolyse/Desafib, American Diagnostica). Normal ranges are 0.01-0.8 IU/ml.…”

Section: Methodsmentioning

confidence: 99%

Primary thrombophilia in Mexico: A prospective study

et al. 1999

View full text Add to dashboard Cite

A group of 102 Mexican Mestizo patients with appropriate clinical features suggestive of primary thrombophilia was prospectively studied. Thirty-nine percent of them had activated protein C resistance, but only four patients displayed the factor V Leiden mutation. Five percent of the individuals were found to be protein C deficient, whereas 2% had protein S deficiency. No cases of abnormalities in antithrombin III, plasminogen, tissuetype plasminogen activator or plasminogen activator inhibitor were found. The low prevalence of the activated protein C resistance genotype, probably stemming from the genetic admixture of the Mexican Mestizo group is noteworthy. Am. J. Hematol. 60:1-5, 1999.

show abstract

“…PAI-1 was measured by an amidolytic assay, using the Coatest PAI kit (Chromogenix) [18]. PAP were measured with the ELISA previously described in our laboratory by Montes et al [19].…”

Section: Patientsmentioning

confidence: 99%

Hemostatic markers in surgery: a different fibrinolytic activity may be of pathophysiological significance in orthopedic versus abdominal surgery

López¹,

*²,

Pardo³

et al. 1998

International Journal of Clinical & Laboratory Research

View full text Add to dashboard Cite

Without prophylaxis, patients subjected to major abdominal surgery have a risk of deep vein thrombosis of approximately 30%, while the rate varies between 40% and 60% in orthopedic surgery. The reasons for this discrepancy are not completely understood. The present study was designed to compare the pre-and postoperative behavior of different coagulation and fibrinolysis parameters in patients undergoing both types of surgery, receiving low molecular weight heparin prophylaxis. Samples were taken before operation and on postoperative days 1,3, and 7. The following parameters were assessed: prothrombin fragment 1+2, thrombin-antithrombin III complexes, fibrinopeptide A, tissue plasminogen activator, plasminogen activator inhibitor, plasmin-c~__-antiplasmin complexes, and fibrin degradation products. We found a significant increase in the clotting markers postoperatively compared with preoperative values (P<0.05), both in abdominal and orthopedic surgery, indicating a marked hemostatic activation which remained until postoperative day 7. A significant increase in plasminogen activator inhibitor (P<0.01) and a decrease in tissue plasminogen activator and plasmin-%-antiplasmin complexes was also observed early

show abstract

Evidence for a rapid inhibitor to tissue plasminogen activator in plasma

Cited by 491 publications

References 8 publications

Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus

Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus

Primary thrombophilia in Mexico: A prospective study

Hemostatic markers in surgery: a different fibrinolytic activity may be of pathophysiological significance in orthopedic versus abdominal surgery

Contact Info

Product

Resources

About